Cancer letters, 2013-02, Vol.329 (1), p.109-117
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo
- Ist Teil von
- Cancer letters, 2013-02, Vol.329 (1), p.109-117
- Ort / Verlag
- Ireland: Elsevier Ireland Ltd
- Erscheinungsjahr
- 2013
- Quelle
- Access via ScienceDirect (Elsevier)
- Beschreibungen/Notizen
- Highlights ► Sorafenib could potentiate irradiation effect in two HCC cells and their xenografts. ► Inhibition of radiation-induced proliferation and DNA repair capacity by sorafenib may be underlying mechanisms for synergy. ► Promotion of radiation-induced apoptosis by sorafenib may also contribute to the potential effect of irradiation and sorafenib.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0304-3835eISSN: 1872-7980DOI: 10.1016/j.canlet.2012.10.024Titel-ID: cdi_proquest_miscellaneous_1273119116
- Format
- –
- Schlagworte
- Animals, apoptosis, Apoptosis - drug effects, Apoptosis - radiation effects, Carcinoma, Hepatocellular - drug therapy, Carcinoma, Hepatocellular - metabolism, Carcinoma, Hepatocellular - pathology, Carcinoma, Hepatocellular - radiotherapy, Cell Line, Tumor, Combined Modality Therapy, DNA damage, DNA Damage - drug effects, DNA repair, DNA Repair - drug effects, DNA Repair - radiation effects, Female, Hematology, Oncology and Palliative Medicine, Hepatocellular carcinoma, hepatoma, humans, In vitro, irradiation, Liver Neoplasms - drug therapy, Liver Neoplasms - metabolism, Liver Neoplasms - pathology, Liver Neoplasms - radiotherapy, MAP Kinase Signaling System - drug effects, Mice, Mice, Inbred BALB C, mitogen-activated protein kinase, NF-kappa B - metabolism, Niacinamide - analogs & derivatives, Niacinamide - pharmacology, Phenylurea Compounds - pharmacology, Phosphorylation, Radiation-Sensitizing Agents - pharmacology, Radiotherapy, Sorafenib, vascular endothelial growth factor receptor-2, Vascular Endothelial Growth Factor Receptor-2 - metabolism, Xenograft model, Xenograft Model Antitumor Assays